Authored by: mrisch on Sunday, July 15 2012 @ 08:03 PM EDT |
The final takeaway from my last comment (and my article) is my
primary criticism of this article - I bet if you did the same
study for practicing entities - even with cross-licenses - the
costs would be even higher - certainly higher per case. That's
the study I would like to see.
This is not to say that NPEs aren't costly - only that you
can't consider them in a vacuum when you think of all the weak
patents asserted by productive companies.[ Reply to This | Parent | # ]
|
- BTW... - Authored by: PJ on Sunday, July 15 2012 @ 09:33 PM EDT
|
Authored by: mrisch on Sunday, July 15 2012 @ 08:16 PM EDT |
I should also make clear - our data ends in 2010, and I think
IV's subsidiary suit activity didn't ramp up a lot until after
that - I certainly didn't have the data. Another article,
called "The Giants Among Us" tracks IV's activity if you're
interested.[ Reply to This | Parent | # ]
|
|
Authored by: PJ on Sunday, July 15 2012 @ 09:37 PM EDT |
Ah! So NPEs are no worse than Monsanto, another
argument not likely to do well here.
: )[ Reply to This | Parent | # ]
|
|